The BCL10 gene has recently been cloned from the 1p22 breakpoint of the translocation t(1;14)(p22;q32) observed in mucosaassociated lymphoid tissue (MALT) lymphoma. BCL10 was shown to be a proapoptotic-signaling gene encoding a protein that contains an amino-terminal caspase recruitment domain (CARD). Mutations within the BCL10 coding region resulting in truncated BCL10 proteins with loss of their proapoptotic function and preservation of their NF-B activating function were detected in MALT lymphoma. Based on these findings it was proposed that BCL10 might have tumor suppressor function. Deletions involving 1p22 are commonly observed in mantle cell lymphoma (MCL). To investigate its role in MCL we have analyzed a series of 15 MCL for deletion and mutation of BCL10. Monoallelic 1p22 deletions were detected by fluorescence in situ hybridization in five of the 15 cases and were shown to affect BCL10 in all cases. BCL10 was screened for mutations by DNA sequencing of RT-PCR amplified transcripts. In none of the 15 MCL cases studied were mutations found in the BCL10 coding region. A previously reported polymorphism exhibiting a silent 24C Ͼ G substitution was found in eight MCL cases and in four healthy probands. A missense mutation 13G ϾT resulting in a substitution of a serine by an alanine was seen in one of the controls. Our results strongly suggest that BCL10 is not the candidate tumor suppressor gene inactivated by deletion or mutation in band 1p22 in MCL.
Introduction
Mantle cell lymphoma (MCL) is a malignant lymphoproliferative disorder derived from a subset of naive pregerminal center cells exhibiting nodular or diffuse proliferation of atypical lymphoid cells with a monoclonal B cell phenotype and coexpression of CD5. 1 Besides the distinct clinical and morphological features, MCL is genetically characterized by the chromosomal translocation t(11;14)(q13;q32). This translocation was shown to result in the juxtaposition of the immunoglobulin heavy-chain joining region (14q32) to the cyclin D1 (CCND1) gene (11q13). 2 This gene rearrangement results in the overexpression of CCND1 which is involved in the regulation of G1-S phase transition of the cell cycle. As cyclin D1 overexpression is detected in almost all cases of MCL, the deregulation of CCND1 is considered a significant pathogenic mechanism. However, experiments with transgenic animals have shown that in addition to the overexpression of cyclin D1 other oncogenic factors such as c-MYC are required for the generation of B cell lymphomas. 3, 4 Therefore, it was suggested that in addition to the BCL1 rearrangement other genetic events are necessary for the malignant transformation of MCL cells. In MCL, aberrations other than the t(11;14)(q13;q32) are less well defined. By means of cytogenetics and molecular cytogenetics, numerous recurrent alterations have been observed. [5] [6] [7] [8] Loss of the chromosome region 1p22 was one of the most frequent aberrations seen in these studies. In a comprehensive fluorescence in situ hybridization (FISH) analysis of 62 MCL cases deletions of 1p22 were detected in 34%. 9 A gene designated BCL10 has recently been cloned from the 1p22 breakpoint of the translocation t(1;14)(p22;q32) in mucosa-associated lymphoid tissue (MALT) lymphoma. 10, 11 The protein encoded by BCL10 is a homologue of the equine herpesvirus-2 E10 gene product containing an amino-terminal caspase recruitment domain (CARD) similar to that found in proapoptotic proteins. 12 In MALT lymphoma with the t(1;14)(p22;q32) BCL10 was altered by frameshift mutations resulting in truncation of the protein beyond the CARD. Cells expressing truncated proteins failed to undergo apoptosis but retained the function to activate the transcription factor NF-B.
10-12 Due to its mutational disruption in MALT lymphoma BCL10 was proposed to act as a tumor suppressor gene. To evaluate the potential involvement of BCL10 in the pathogenesis of MCL, we analyzed a series of 15 MCL for deletions and mutations of this gene.
Materials and methods
Tumor samples were obtained from 15 patients with MCL and peripheral blood was obtained from 10 healthy probands. Diagnoses were based on established criteria. 1 All MCL tumors included in this study carried the translocation t(11;14)(q13;q32) as detected by our interphase cytogenetic probe set. 13 Dual-color FISH was performed to detect 1p22 deletions in MCL as previously described.
14 The P1-derived artificial chromosome (PAC) clones 33c22, 224i04 and 211k24 containing BCL10 were used as probes. 11 Control experiments were performed on metaphase cells of healthy individuals and the cut-off level for the diagnosis of deletions in interphase cells was determined as previously reported. 14 Signal number was enumerated in 200 nuclei.
Total RNA was isolated from the MCL samples and from mononuclear cells of healthy probands using the RNeasy Mini Protocol (RNeasy Mini Kit, Qiagen, Hilden, Germany) or the Trizol reagent (Gibco BRL, Karlsruhe, Germany). The entire open reading frame (ORF) of BCL10 was amplified by RT-PCR with the primer pair published by Willis et al. 10 After purification of the PCR product (QIAquick PCR Purification Kit, Qiagen), sequencing of both DNA strands was performed using the primers 5′-GTTGTTCGTGGCTCC ATCTG-3′, 5′-ACAGATGAAGTGCTGAAACTTAG-3′ and the RT-PCR primers. 10 Automated sequencing was carried out with the ABI BigDye Terminator Cycle Sequencing Ready Reaction DNA Sequencing Kit and the ABI 310 or 377 automated sequencer (Perkin-Elmer Applied Biosystems, Weiterstadt, Germany).
Amplification of genomic DNA by PCR and subsequent sequencing of the products was performed with the primers 5′-CAGCTAAGACTGCCAACT-3′, 5′-CAACAA GGGTGTCCA GACCT-3′ and the primers described by Willis et al.
10

Results and discussion
To screen for abnormalities of the short arm of chromosome 1, three PAC clones of the BCL10 locus were used separately as FISH probes in a series of 15 MCL. Cut-off levels for the diagnosis of chromosomal 1p22 loss with PAC clones 33c22, 224i04 and 211k24 were determined at 4.8%, 3.6% and 4.1%, respectively. Five of the 15 MCL examined, showed 1p22 deletions. All five deletions were detected with each of the three PAC clones. The percentage of cells carrying the deletion ranged from 61 to 93%, with a median of 76%. No biallelic deletion was observed. The recently cloned BCL10 gene localized in 1p22 appeared as a likely candidate tumor suppressor gene being disrupted by loss of 1p22 in MCL.
BCL10 was therefore screened for mutations by DNA sequencing of RT-PCR amplified transcripts. A previously described polymorphism resulting from a 24C Ͼ G substitution within codon 8 was found in eight MCL cases and in four healthy probands (Accession No. AJ006288). 10 Another published polymorphism was identified in one healthy proband: a 13G Ͼ T substitution 11 caused an amino acid exchange (Ala5Ser). The effect of this missense mutation on the function of the protein remains to be determined. The other seven MCL cases and six healthy probands revealed the sequence according to the Accession No. AF082283 11 (Table 1) .
Besides the polymorphisms mentioned above no other sequence alterations were found in MCL. In agreement with our data, several groups failed to detect any abnormality of BCL10 in a wide variety of solid tumors. [15] [16] [17] [18] [19] In particular, in B cell neoplasms BCL10 mutations were observed as very rare events. [20] [21] [22] Some of the discrepancies between the initial reports of mutations in MALT lymphoma 10, 11 and the subsequent data [15] [16] [17] [18] [19] [20] [21] [22] were ascribed to post-transcriptional modification resulting in sequence alterations detectable on the Leukemia cDNA but not on the genomic DNA level. 23, 24 However, this mechanism of BCL10 disruption was not observed in our study based on RNA analysis. It was also suggested that the initial findings could be attributed to sequence changes that had occurred during the cloning procedures. 25 Therefore, in our study direct sequencing of RT-PCR products was used to avoid potential cloning artifacts.
A previously described phenomenon 26 most likely caused by polymerase slippage was observed in a homopolymeric run of eight As (BCL10 ORF position 129A to 136A, Accession No. AJ006288 10 ). In all MCL cases, DNA sequence analysis of RT-PCR products detected a minor percentage of molecules containing only seven instead of eight As, which resulted in a frameshift (see Figure 1) . However, this observation may not be regarded as a tumor-associated mutation but more likely represents a result of polymerase slippage taking place during PCR or sequencing reactions: (1) the alteration was observed in all MCL cases studied irrespective of their BCL10 deletion status; (2) the phenomenon was observed in all healthy controls to the same extent as in MCL; (3) alterations introduced during or after transcription could be excluded, as the same phenomenon was observed when PCR products amplified from genomic DNA were sequenced.
Recently BCL10 was found disrupted in MALT lymphoma and in a variety of solid tumors in two reports. 10, 11 However, in our study BCL10 was not mutated in 15 MCL, five of which exhibited 1p22 deletion. Therefore our data suggest that BCL10 is not the tumor suppressor gene disrupted by deletion and mutation in band 1p22 in MCL. 
